Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 12, 2015, Pages 1456-1462

  Solberg, Inger Camilla ^a   Høivik, Marte Lie ^a   Cvancarova, Milada ^b   Moum, Bjørn ^a,b   Vatn, Morten ^a   Lygren, Idar ^a   Jahnsen, Jørgen ^c   Høie, Ole ^d   Henriksen, Magne ^e   Stray, Njål ^f   Bernklev, Tomm ^g   Sauar, Jostein ^g  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d Sørlandet Hospital   (Norway)

^e Østfold Hospital   (Norway)

^f DIAKONHJEMMET HOSPITAL   (Norway)

^g TELEMARK HOSPITAL   (Norway)

Author keywords

colectomy; population based; prognosis; risk factors; ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; GLUCOCORTICOID; HEMOGLOBIN; MERCAPTOPURINE; MESALAZINE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COLON RESECTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TREATMENT RESPONSE; ULCERATIVE COLITIS; WEIGHT REDUCTION; ADOLESCENT; BLOOD; CHEMISTRY; CLINICAL TRIAL; COLITIS, ULCERATIVE; MIDDLE AGED; MULTICENTER STUDY; NORWAY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; GLUCOCORTICOIDS; HEMOGLOBINS; HUMANS; LOGISTIC MODELS; MALE; MESALAMINE; MIDDLE AGED; NORWAY; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938603092     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1064991     Document Type: Article

References (26)

1. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
2. Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992;103:954-60.
3. Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102: 1692-701.
4. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-45.
5. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260-6.
6. Solberg IC, Lygren I, Jahnsen J, Aadland E, Hoie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44: 431-40.
7. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
8. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology 2009;48: 1114-21.
9. Solberg IC, Cvancarova M, Vatn MH, Moum B, Group IS. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study). Inflamm Bowel Dis 2014;20:60-8.
10. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543-50.
11. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut 1997;40:328-32.
12. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large. prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997;32:1005-12.
13. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543-50.
14. Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol 2006;41:1037-43.
15. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8.
16. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008;2:1-23.
17. Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J gastroenterol 2012;18:3806-13.
18. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000;14:273-9.
19. Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483-9; e3.
20. Allez M, Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 2010;16:2626-32.
21. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, Gisbert JP, Gallardo-Valverde JM, Gonzalez-Galilea A, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010;4:144-52.
22. Lasson A, Simren M, Stotzer PO, Isaksson S, Ohman L, Strid H. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis 2013;19:576-81.
23. Ardizzone S, Cassinotti A, Penati CM, Duca P, Massan A, Manes G, et al. Clinical and endoscopic outcome after the first corticosteroid course in newly diagnosed ulcerative colitis: A 5-years follow-up inception cohort study. Gastroenterology 2007;132:A16-A.
24. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132: 763-86.
25. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-82.
26. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-15.